ImetelChat

I posted this as part of a private interaction with a well respected poster. I am just putting it out there, admittedly based on not much. Ok, so my MF thesis is that mod/high risk patients not infrequently develop AML and this is one significant modus exodus. This is of course why they get classifi...

Hi Phil, thanks for posting. I couldn't agree more with your assessment. EU approval has been telegraphed. There are a few mysteries worth examining. The GC's sale is not one of them for all the reasons you enumerate. Scarlett has acted as if he remained uncertain about the CD, but of course he knew...

Phil, thank you. Your track record is pretty pretty good (to quote Larry David). It does look like there is a lot of interest in Europe. Interestingly the job posting at Janssen does not mention MF but emphasizes MDS and AML (!) in patients not eligible for induction. Perhaps MF approval is a forgon...

Part II: Sergei of course was the true father of Imetelstat. He apparently made a soft landing at Janssen so I won't include him on this list as he is not strictly now an academic but I think we will hear much more about him in the coming months. His contribution and brilliance is enormous as are hi...

As some of you know from private communications, I have been retired for about 6 weeks which has provided me with ample time for reflection. It has been my pleasure to moderate this board and I was truly honored when Fish Sr. asked me to take this on. It is hardly onerous as virtually all contributo...

J6, I have interpreted this a little differently and (perhaps less optimistically.). As I recall, GRN1005 was based a a vehicle that permeated the blood brain barrier and was hoped to allow easier entry for an Imetelstat conjugation into the CNS. After evaluation the license was returned to the (I t...

MTB, we are very fortunate to have you here, thank you for joining. Sorry for the bumps in the road. We can thank Fish Jr. for getting the registration process straightened out. I hope things will be easier now for you and all other board members going forward. bp

J6, very nice find. I haven’t looked at the GRN1005 study for years and yet there are all 49 (!!!) updates. Geron said the FDA would look at the totality of the data and I guess they are sure lookin’! Interesting that the study has changed from a therapeutic study to a diagnostic one. bp

Nuts, I am not one for conspiracy theories, but whatever happened it is unlikely the FDA will withstand the weight of Janssen as opposed to the days when Geron was going it alone. When the curious hold happened it was a "partial" hold not a "complete" hold so some patients contin...

Nuts, agreed, you will get no argument from me. JAK inhibitors reduce spleen size but do not appear to prolong life once one gets to the R/R stage, in fact by definition, therapy with JAK inhibitors does not help this group. So as with many therapies, symptom improvement comes with a price, includin...

Here's the reference: No mention of Imetelstat in article or references. Mainly describes possible increased risk of lymphoma (B-cell) and JAK inhibition.

http://www.bloodjournal.org/content/132 ... ecked=true

dongonenuts, Here's the reference, its an open article and is readily accessible, Dr T is one of the authors. I think we have discussed it before and ideally I would like to provide access via the library but as you know that's a work in progress! Regards, bp How I treat myelofibrosis after failure ...

J6, thank you for posting. This patent as Cheng points out was provisional but now as you have kindly posted appears to have been issued. Note the provision for oral administration. As yet we know nothing about potential synergism in vivo but it sure is interesting. Again thank you for your research...

Cheng, Very funny, very funny. I looked too and couldn't find it, must just be looking in the wrong place (or the wrong time). bp

Hat tip to PEDMAC2000 YMB: this is from the Shay Wright lab and is current:
https://www.utsouthwestern.edu/labs/sha ... erase.html

It looks like several new members are here. Welcome. Just a note and a reminder. 1. If you choose an offensive user name, you will not be approved. 2. If your email looks like a bot (we have learned...) don't bother, you will not be approved. The vast majority of posters are posting thoughtful contr...

Ryan, I agree with your points and with Hunt. The conference call was really just treading water. "Derisked", we know we know. Can't say anything until ASH, we know we know. We are ready to go it alone...thank you John we know, we know. So other than the info re the shelf offering there wa...

Patent application by Janssen with applicability to a multitude of malignancies. Combination therapy Imetelstat and BCL 2 inhibitors. Hat tip to PEDMAC2000: https://patents.google.com/patent/US20180036336A1/en

Welcome to you both and to all new members, it’s going to get interesting, that’s for sure. bp

Very worth a careful read:
https://seekingalpha.com/article/418977 ... imetelstat